TY - JOUR
T1 - Advances in stroke pharmacology
AU - Zhou, Zhenhua
AU - Lu, Jianfei
AU - Liu, Wen Wu
AU - Manaenko, Anatol
AU - Hou, Xianhua
AU - Mei, Qiyong
AU - Huang, Jun Long
AU - Tang, Jiping
AU - Zhang, John H.
AU - Yao, Honghong
AU - Hu, Qin
N1 - Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/11
Y1 - 2018/11
N2 - Stroke occurs when a cerebral blood vessel is blocked or ruptured, and it is the major cause of death and adult disability worldwide. Various pharmacological agents have been developed for the treatment of stroke either through interrupting the molecular pathways leading to neuronal death or enhancing neuronal survival and regeneration. Except for rtPA, few of these agents have succeeded in clinical trials. Recently, with the understanding of the pathophysiological process of stroke, there is a resurrection of research on developing neuroprotective agents for stroke treatment, and novel molecular targets for neuroprotection and neurorestoration have been discovered to predict or offer clinical benefits. Here we review the latest major progress of pharmacological studies in stroke, especially in ischemic stroke; summarize emerging potential therapeutic mechanisms; and highlight recent clinical trials. The aim of this review is to provide a panorama of pharmacological interventions for stroke and bridge basic and translational research to guide the clinical management of stroke therapy.
AB - Stroke occurs when a cerebral blood vessel is blocked or ruptured, and it is the major cause of death and adult disability worldwide. Various pharmacological agents have been developed for the treatment of stroke either through interrupting the molecular pathways leading to neuronal death or enhancing neuronal survival and regeneration. Except for rtPA, few of these agents have succeeded in clinical trials. Recently, with the understanding of the pathophysiological process of stroke, there is a resurrection of research on developing neuroprotective agents for stroke treatment, and novel molecular targets for neuroprotection and neurorestoration have been discovered to predict or offer clinical benefits. Here we review the latest major progress of pharmacological studies in stroke, especially in ischemic stroke; summarize emerging potential therapeutic mechanisms; and highlight recent clinical trials. The aim of this review is to provide a panorama of pharmacological interventions for stroke and bridge basic and translational research to guide the clinical management of stroke therapy.
KW - Animal studies
KW - Clinical trials
KW - Neuroprotection
KW - Pharmacology
KW - Stroke
KW - Brain Ischemia/drug therapy
KW - Humans
KW - Stroke/drug therapy
KW - Drug Development/methods
KW - Molecular Targeted Therapy
KW - Neuroprotective Agents/pharmacology
KW - Animals
KW - Translational Research, Biomedical/methods
UR - http://www.scopus.com/inward/record.url?scp=85048896264&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048896264&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/b072cabb-2d36-3985-adfe-298e06911d0b/
U2 - 10.1016/j.pharmthera.2018.05.012
DO - 10.1016/j.pharmthera.2018.05.012
M3 - Article
C2 - 29807056
SN - 0163-7258
VL - 191
SP - 23
EP - 42
JO - Pharmacology and Therapeutics
JF - Pharmacology and Therapeutics
ER -